Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Galapagos NV (GLPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,781,870
  • Shares Outstanding, K 51,235
  • Annual Sales, $ 375,370 K
  • Annual Income, $ -34,550 K
  • 60-Month Beta 1.63
  • Price/Sales 15.59
  • Price/Cash Flow N/A
  • Price/Book 4.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.15
  • Number of Estimates 6
  • High Estimate -0.30
  • Low Estimate -1.66
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -130.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
110.92 +1.74%
on 05/13/19
117.31 -3.80%
on 05/10/19
-1.13 (-0.99%)
since 04/17/19
3-Month
94.75 +19.10%
on 03/27/19
125.48 -10.07%
on 04/05/19
+9.73 (+9.44%)
since 02/15/19
52-Week
85.00 +32.76%
on 12/27/18
125.48 -10.07%
on 04/05/19
+16.17 (+16.73%)
since 05/17/18

Most Recent Stories

More News
Galapagos reports on historic first quarter 2019

Key Q1 2019 results:

GLPG : 112.85 (-1.27%)
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Mechelen, Belgium and Planegg/Munich, Germany; 23 April 2019; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Novartis Pharma...

MOR : 26.00 (-1.22%)
GLPG : 112.85 (-1.27%)
Galapagos creates new warrant plans

Mechelen, Belgium; 10 April 2019, 22.01 CET; regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 2,070,000 warrants under new warrant plans...

GLPG : 112.85 (-1.27%)
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy

Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.

AGEN : 2.95 (unch)
GILD : 66.36 (+0.88%)
GLPG : 112.85 (-1.27%)
GSK : 39.46 (+0.31%)
Investor Expectations to Drive Momentum within Cisco, NanoString Technologies, Galapagos NV, A10 Networks, International Seaways, and Scholastic -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cisco Systems, Inc. (NASDAQ:CSCO),...

ATEN : 6.43 (-0.16%)
SCHL : 37.22 (-0.32%)
CSCO : 56.35 (+0.75%)
INSW : 19.43 (-3.81%)
NSTG : 26.85 (-3.35%)
GLPG : 112.85 (-1.27%)
Publication of the annual report and invitation to the annual shareholders' meeting

Nomination of Mr. Peter Guenter for Galapagos' board of directors

GLPG : 112.85 (-1.27%)
Progress Software up, RH slides

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:

OXM : 74.10 (+0.23%)
RH : 94.20 (-2.95%)
PRGS : 43.25 (-0.78%)
EXP : 91.07 (-0.56%)
GLPG : 112.85 (-1.27%)
SAIC : 78.30 (+0.05%)
Gilead & Galapagos Announce Positive Data on Arthritis Drug

Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.

AGEN : 2.95 (unch)
ABBV : 79.46 (-0.05%)
GILD : 66.36 (+0.88%)
GLPG : 112.85 (-1.27%)
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)

GILD : 66.36 (+0.88%)
GLPG : 112.85 (-1.27%)
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)

-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile --

GILD : 66.36 (+0.88%)
GLPG : 112.85 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade GLPG with:

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

2nd Resistance Point 114.15
1st Resistance Point 113.50
Last Price 112.85
1st Support Level 112.41
2nd Support Level 111.98

See More

52-Week High 125.48
Last Price 112.85
Fibonacci 61.8% 110.02
Fibonacci 50% 105.24
Fibonacci 38.2% 100.46
52-Week Low 85.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar